Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 25
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis.

  • Díaz Ruiz, Raquel
  • Rapado Castro, Marta
  • Bretón Lesmes, Irene
  • Bañares Cañizares, Rafael
  • García Martínez, Rita
Background/Objectives: Decompensated cirrhosis is characterized by systemic inflammation and innate and adaptive immune dysfunction. Hepatic encephalopathy (HE) is a prevalent and debilitating condition characterized by cognitive disturbances in which ammonia and inflammation play a synergistic pathogenic role. Extraskeletal functions of vitamin D include immunomodulation, and its deficiency has been implicated in immune dysfunction and different forms of cognitive impairment. The aim was to assess changes in cognitive function and inflammation in decompensated patients with cirrhosis receiving vitamin D supplementation. Methods: Patients with cirrhosis discharged from decompensation in two tertiary hospitals in Spain (from September 2017 to January 2020) were assessed before, at 6 and 12 months after vitamin D supplementation. A comprehensive neuropsychological battery and neuroinflammatory markers were examined. In a subgroup of patients, peripheral immune blood cells were analyzed. Results: Thirty-nine patients were recruited. Of those, 27 completed the 6 months evaluation and were analyzed [age 62.4 ± 11.3 years; 22 men; Model for End-Stage Liver Disease (MELD) 11.7 ± 4.0; prior overt HE 33%; median 25-hydroxyvitamin D (25OHD) plasma level 12.7 µgr/L] and 22 achieved 12 months assessment. At baseline, learning and memory (R = 0.382; p = 0.049) and working memory (R = 0.503; p = 0.047) subtests correlated with plasma 25OHD levels. In addition, processing speed (R = −0.42; p = 0.04), attention (R = −0.48; p = 0.04), Tinnetti balance (R = −0.656; p < 0.001) and Tinnetti score (R = −0.659; p < 0.001) were linked to neuroinflammation marker IL-1β. Patients with lower 25OHD had a greater proportion of TH1cells at baseline and a larger amelioration of IL-1β and IL-6 following supplementation. An improvement in working memory was found after 25OHD replacement (46.7 ± 13 to 50 ± 11; p = 0.047). Conclusions: This study supports that vitamin D supplementation modulates low-grade inflammation in decompensated cirrhosis providing cognitive benefits, particularly in working memory.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The reproductive status determines tolerance and resistance to Mycobacterium marinum in Drosophila melanogaster

  • Arch Sisquella, Marta|||0000-0002-2120-1667
  • Vidal Ramos, Maria|||0000-0003-2705-9873
  • Fuentes, Esther|||0000-0002-6151-8204
  • Abat, Anmaw Shite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
Sex and reproductive status of the host have a major impact on the immune response against infection. Our aim was to understand their impact on host tolerance or resistance in the systemic Mycobacterium marinum infection of Drosophila melanogaster. We measured host survival and bacillary load at time of death, as well as expression by quantitative real-time polymerase chain reaction of immune genes (diptericin and drosomycin). We also assessed the impact of metabolic and hormonal regulation in the protection against infection by measuring expression of upd3, impl2 and ecR. Our data showed increased resistance in actively mating flies and in mated females, while reducing their tolerance to infection. Data suggests that Toll and immune deficiency (Imd) pathways determine tolerance and resistance, respectively, while higher basal levels of ecR favours the stimulation of the Imd pathway. A dual role has been found for upd3 expression, linked to increased/decreased mycobacterial load at the beginning and later in infection, respectively. Finally, impl2 expression has been related to increased resistance in non-actively mating males. These results allow further assessment on the differences between sexes and highlights the role of the reproductive status in D. melanogaster to face infections, demonstrating their importance to determine resistance and tolerance against M. marinum infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment of Vitamin D Deficiency in Decompensated Patients with Cirrhosis Is Associated with Improvement in Frailty

  • Díaz Ruíz, Raquel|||0000-0002-2259-0289
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Roman, Eva|||0000-0001-9084-8555
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Bañares, Irene
  • Morales, Ángela
  • Hernández Martínez-Esparza, Elvira|||0000-0002-9736-9052
  • Panadero, Rocío
  • Velasco, Cristina
  • Rapado-Castro, Marta|||0000-0001-8484-6051
  • Breton, Irene|||0000-0003-0263-3728
  • Bañares, Rafael|||0000-0002-0412-8437
  • Soriano, German|||0000-0002-9267-6811
  • García Martínez, Rita|||0000-0003-2159-2757
Background/aim : Frailty is increasingly recognized as a relevant prognostic factor in patients with cirrhosis, regardless of liver failure. Vitamin D deficiency is frequent in these patients and has been related to frailty and sarcopenia, but the impact of its supplementation on frailty in cirrhosis is unknown. The aim was to evaluate the effect of vitamin D supplementation on frailty in patients with decompensated cirrhosis and vitamin D deficiency or insufficiency. Methods : We included patients with cirrhosis who had vitamin D deficiency or insufficiency following their hospitalization for acute decompensation. Vitamin D was supplemented according to current recommendations, as were other micronutrients if necessary. Patients were followed for one year to evaluate changes at 6 and 12 months in frailty (Fried frailty index), health-related quality of life (SF-36, CLDQ) and mood (HADS). Body composition was assessed by DXA at baseline and at 12 months. Results : We included 39 patients, 27 of whom reached the 6-month follow-up. Serum vitamin D increased at 6 and 12 months (p < 0.001 compared to baseline). Fried frailty index improved at the 6-month visit (p = 0.004), and handgrip strength improved at 6 (p = 0.001) and 12 (p = 0.002) months, similarly in women and men. At 12 months, we observed an increase in body mass index, right arm lean mass and total fat mass. Conclusions : A multifactorial nutritional intervention, especially vitamin D supplementation after discharge in decompensated, vitamin D-deficient patients with cirrhosis, was associated with an improvement in frailty, muscular strength and lean muscle mass. However, the increase in fat mass strengthens the recommendation for diet, exercise and weight supervision.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis

  • Díaz Ruíz, Raquel|||0000-0002-2259-0289
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Roman, Eva|||0000-0001-9084-8555
  • Panadero, Rocío
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Bañares, Irene
  • Morales, Ángela
  • Puerto, Marta|||0000-0002-1263-9296
  • Lopez-Esteban, Rocio
  • Blazquez, Elena
  • Fernández-Castillo, Marta
  • Correa-Rocha, Rafael|||0000-0003-3456-9986
  • Rapado-Castro, Marta|||0000-0001-8484-6051
  • Breton, Irene|||0000-0003-0263-3728
  • Bañares, Rafael|||0000-0002-0412-8437
  • Soriano, German|||0000-0002-9267-6811
  • García Martínez, Rita|||0000-0003-2159-2757
Background/Objectives: Decompensated cirrhosis is characterized by systemic inflammation and innate and adaptive immune dysfunction. Hepatic encephalopathy (HE) is a prevalent and debilitating condition characterized by cognitive disturbances in which ammonia and inflammation play a synergistic pathogenic role. Extraskeletal functions of vitamin D include immunomodulation, and its deficiency has been implicated in immune dysfunction and different forms of cognitive impairment. The aim was to assess changes in cognitive function and inflammation in decompensated patients with cirrhosis receiving vitamin D supplementation. Methods : Patients with cirrhosis discharged from decompensation in two tertiary hospitals in Spain (from September 2017 to January 2020) were assessed before, at 6 and 12 months after vitamin D supplementation. A comprehensive neuropsychological battery and neuroinflammatory markers were examined. In a subgroup of patients, peripheral immune blood cells were analyzed. Results : Thirty-nine patients were recruited. Of those, 27 completed the 6 months evaluation and were analyzed [age 62.4 ± 11.3 years; 22 men; Model for End-Stage Liver Disease (MELD) 11.7 ± 4.0; prior overt HE 33%; median 25-hydroxyvitamin D (25OHD) plasma level 12.7 µgr/L] and 22 achieved 12 months assessment. At baseline, learning and memory (R = 0.382; p = 0.049) and working memory (R = 0.503; p = 0.047) subtests correlated with plasma 25OHD levels. In addition, processing speed (R = -0.42; p = 0.04), attention (R = -0.48; p = 0.04), Tinnetti balance (R = -0.656; p < 0.001) and Tinnetti score (R = -0.659; p < 0.001) were linked to neuroinflammation marker IL-1β. Patients with lower 25OHD had a greater proportion of TH1cells at baseline and a larger amelioration of IL-1β and IL-6 following supplementation. An improvement in working memory was found after 25OHD replacement (46.7 ± 13 to 50 ± 11; p = 0.047). Conclusions : This study supports that vitamin D supplementation modulates low-grade inflammation in decompensated cirrhosis providing cognitive benefits, particularly in working memory.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain

  • Racz, Ildiko
  • Nadal i Roura, Xavier, 1980-
  • Alferink, Judith
  • Baños i Díez, Josep Eladi
  • Rehnelt, Jennifer
  • Martín Sánchez, Miquel, 1971-
  • Pintado, Belén
  • Gutierrez-Adan, Alfonso
  • Sanguino, Elena
  • Manzanares, Jorge
  • Zimmer, Andreas
  • Maldonado, Rafael, 1961-
Neuropathic pain is a clinical manifestation of nerve injury difficult to treat even with potent analgesic compounds. Here, we used different lines of genetically modified mice to clarify the role played by CB2 cannabinoid receptors in the regulation of the central immune responses leading to the development of neuropathic pain. CB2 knock-out mice and wild-type littermates were exposed to sciatic nerve injury, and both genotypes developed a similar hyperalgesia and allodynia in the ipsilateral paw. Most strikingly, knock-outs also developed a contralateral mirror image pain, associated with an enhanced microglial and astrocytic expression in the contralateral spinal horn. In agreement, hyperalgesia, allodynia, and microglial and astrocytic activation induced by sciatic nerve injury were attenuated in transgenic mice overexpressing CB2 receptors. These results demonstrate the crucial role of CB2 cannabinoid receptor in modulating glial activation in response to nerve injury. The enhanced manifestations of neuropathic pain were replicated in irradiated wild-type mice reconstituted with bone marrow cells from CB2 knock-outs, thus demonstrating the implication of the CB2 receptor expressed in hematopoietic cells in the development of neuropathic pain at the spinal cord., This work was supported by grants from the National Institute on Drug Abuse (1R01-DA016768-0111) (R.M.,A.Z.), European Commission [Framework VI, GENADDICT OJ 2004/C164, 005166 (R.M., A.Z.); PHECOM, LSHM-CT-2007-037669 (R.M.)], Ministerio de Educación y Ciencia (BFU2004-00920/BFI; SAF2007-64062) (R.M.), Generalitat de Catalunya (R.M.), Deutsche Forschungsgemeinschaft (SFB645; FOR926) (A.Z.), and Bundesministerium für Bildung und Forschung (NGFN2) (A.Z.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain

  • Racz, Ildiko
  • Nadal i Roura, Xavier, 1980-
  • Alferink, Judith
  • Baños i Díez, Josep Eladi
  • Rehnelt, Jennifer
  • Martín, Miguel
  • Pintado, Belén
  • Gutierrez-Adan, Alfonso
  • Sanguino, Elena
  • Bellora Pereyra, Nicolás
  • Manzanares, Jorge
  • Zimmer, Andreas
  • Maldonado, Rafael, 1961-
Nerve injuries often lead to neuropathic pain syndrome. The mechanisms contributing to this syndrome involve local inflammatory responses, activation of glia cells, and changes in the plasticity of neuronal nociceptive pathways. Cannabinoid CB(2) receptors contribute to the local containment of neuropathic pain by modulating glial activation in response to nerve injury. Thus, neuropathic pain spreads in mice lacking CB(2) receptors beyond the site of nerve injury. To further investigate the mechanisms leading to the enhanced manifestation of neuropathic pain, we have established expression profiles of spinal cord tissues from wild-type and CB(2)-deficient mice after nerve injury. An enhanced interferon-gamma (IFN-gamma) response was revealed in the absence of CB(2) signaling. Immunofluorescence stainings demonstrated an IFN-gamma production by astrocytes and neurons ispilateral to the nerve injury in wild-type animals. In contrast, CB(2)-deficient mice showed neuronal and astrocytic IFN-gamma immunoreactivity also in the contralateral region, thus matching the pattern of nociceptive hypersensitivity in these animals. Experiments in BV-2 microglia cells revealed that transcriptional changes induced by IFN-gamma in two key elements for neuropathic pain development, iNOS (inducible nitric oxide synthase) and CCR2, are modulated by CB(2) receptor signaling. The most direct support for a functional involvement of IFN-gamma as a mediator of CB(2) signaling was obtained with a double knock-out mouse strain deficient in CB(2) receptors and IFN-gamma. These animals no longer show the enhanced manifestations of neuropathic pain observed in CB(2) knock-outs. These data clearly demonstrate that the CB(2) receptor-mediated control of neuropathic pain is IFN-gamma dependent., This work was supported by grants from the National Institute on Drug Abuse (1R01-DA016768-0111) (R.M.,A.Z.), European Commission [Framework VI, GENADDICT OJ 2004/C164, 005166 (R.M., A.Z.); PHECOM, LSHM-CT-2007-037669 (R.M.)], Ministerio de Educación y Ciencia (BFU2004-00920/BFI; SAF2007-64062) (R.M.), Generalitat de Catalunya (R.M.), Deutsche Forschungsgemeinschaft (SFB645; FOR926) (A.Z.), and Bundesministerium für Bildung und Forschung (NGFN2) (A.Z.)
Repisalud
Publicación Artículo científico (JournalArticle)

Performance of the Idylla microsatellite instability test in endometrial cancer

  • Mendiola, Marta
  • Heredia-Soto, Victoria
  • Ruz-Caracuel, Ignacio
  • Baillo, Amparo
  • Ramon-Patino, Jorge Luis
  • Berjon, Alberto
  • Escudero Ruiz, Francisco Javier
  • Peláez-García, Alberto
  • Hernandez, Alicia
  • Feliu, Jaime
  • Hardisson, David
  • Redondo, Andres
Context: DNA mismatch repair (MMR) deficiency (dMMR) testing is now recommended in endometrial cancer. Defect identification in the molecules participating in this pathway, or the presence of microsatellite instability, are commonly employed for this purpose. Novel methods are continuously evolving to report dMMR/microsatellite instability and to easily perform routine diagnoses. Objective: The main aim of this study was to compare the concordance of the Idylla microsatellite instability test for the identification of dMMR endometrial cancer samples defined by immunohistochemistry and MMR genomic status. Design: We applied the Idylla MSI test to 126 early-stage endometrial cancer cases with MMR testing by immunohistochemistry and genomic characterization (methylation in MLH1 and sequence alterations in MLH1, PMS2, MSH2 and MSH6). Individual markers and overall specific performance indicators were explored. Results: The Idylla platform achieved a higher global concordance rate with MMR genomic status than with immunohistochemistry (75 % and 66 %, respectively). Sensitivity and specificity are also higher (75 % vs 66 % and 96 % vs 90 %, respectively). Clustering analysis split the patients into 2 well-differentiated clusters, the pMMR and the dMMR group, represented by MLH1/PMS2 loss and the MLH1 methylated promoter. Overall, immunohistochemistry and MMR genomic status identified more dMMR cases than did the Idylla test, although correlations were improved with a modified Idylla test cut-off. Conclusions: Performance of the Idylla test was better correlated with MMR genomic status than MMR immunohistochemistry status, which improved with a modified test cut-off. Further studies are needed to confirm the cut-off accuracy.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Weakly supervised deep learning to predict recurrence in low-grade endometrial cancer from multiplexed immunofluorescence images

  • Jiménez Sánchez, Daniel
  • López-Janeiro, Álvaro
  • Villalba-Esparza, María
  • Ariz Galilea, Mikel
  • Kadioglu, Ece
  • Masetto, Ivan
  • Goubert, Virginie
  • Lozano, María Dolores
  • Melero, Ignacio
  • Hardisson, David
  • Ortiz de Solórzano, Carlos
  • Andrea, Carlos de
Predicting recurrence in low-grade, early-stage endometrial cancer (EC) is both challenging and clinically relevant. We present a weakly-supervised deep learning framework, NaroNet, that can learn, without manual expert annotation, the complex tumor-immune interrelations at three levels: local phenotypes, cellular neighborhoods, and tissue areas. It uses multiplexed immunofluorescence for the simultaneous visualization and quantification of CD68 + macrophages, CD8 + T cells, FOXP3 + regulatory T cells, PD-L1/PD-1 protein expression, and tumor cells. We used 489 tumor cores from 250 patients to train a multilevel deep-learning model to predict tumor recurrence. Using a tenfold cross-validation strategy, our model achieved an area under the curve of 0.90 with a 95% confidence interval of 0.83–0.95. Our model predictions resulted in concordance for 96,8% of cases (κ = 0.88). This method could accurately assess the risk of recurrence in EC, outperforming current prognostic factors, including molecular subtyping., This work was supported by Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (ISCIII and FEDER; grants PI21/01547—M.D.L. and C.E.A.; PI17/01723 and PI21/00920—A.L.-J and D.V.), and Fundació La Marató de TV3 (I.M., M.D.L., and C.E.A.). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the paper. We would like to thank Raphaël Sandoz for technical support and troubleshooting.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Impregnation of biodegradable polymer using a pressurized soaking method for food packaging

  • León Marcos, Ludisbel
  • Montes Herrera, Antonio
  • García Casas, Ignacio
  • Valor López, Diego
  • García Casas, Ignacio
  • Machado, Noelia Daiana
  • Pereyra López, Clara María
The Pressurized Soaking Impregnation Method combines the main advantages of supercritical solvent impregnation and the soaking casting technique. This work studied the impregnation of poly(3-hydroxy-butyrate-co3-hydroxy-valerate) (PHB-HV) sheets with mango leaf extracts using this method for its future use as active packaging. The influence of temperature (35–55 ºC), pressure (10, 20–30 MPa), and depressurization rate (0.1–5 MPa/min) on the impregnation loads, antioxidant capacities, and mechanical properties of the impregnated samples were evaluated. In addition, the morphological characteristics, colour characterization, and release of active compounds in a food simulant of the PHB-HV samples impregnated at 30 MPa were analysed. The results showed higher impregnation loads (7.66 % wt.) at 30 MPa, 55 ºC, and a slow depressurization rate (0.1 MPa/min). However, the impregnation of antioxidant compounds did not show the expected behaviour, reaching values lower than 3 %. In addition, the samples that were impregnated at 30 MPa showed colour differences that were perceptible to the human eye. A non-homogeneous distribution of impregnation, cracks, and pores on the surface were also observed. The release study in the D1 food simulant showed good agreement with the Peleg model and a quasi-Fickian diffusion behaviour according to the Korsmeyer-Peppas model. The contact time study in the impregnation at 30 MPa, 35 ºC and 0.1 MPa/min revealed a slight increase in antioxidant capacity after six hours. Furthermore, samples with a more homogeneous colour distribution were obtained.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Functional, Physical, and Volatile Characterization of Chitosan/Starch Food Films Functionalized with Mango Leaf Extract

  • Cejudo Bastante, Cristina
  • Ferreiro González, Marta
  • Romera, Irene
  • Casas Cardoso, Lourdes
  • Mantell Serrano, Casimiro
Active packaging is one of the currently thriving methods to preserve highly perishable foods. Nonetheless, the integration of active substances into the formulation of the packaging may alter their properties—particularly mass transfer properties—and therefore, the active compounds acting. Different formulations of chitosan (CH), starch (ST), and their blends (CH-ST), with the addition of mango leaf extract (MLE) have been polymerized by casting to evaluate their food preservation efficiency. A CH-ST blend with 3% MLE using 7.5 mL of the filmogenic solution proved to be the most effective formulation because of its high bioactivity (ca. 80% and 74% of inhibition growth of S. aureus and E. coli, respectively, and 40% antioxidant capacity). The formulation reduced the water solubility and water vapor permeability while increasing UV protection, properties that provide a better preservation of raspberry fruit after 13 days than the control. Moreover, a novel method of Headspace-Gas Chromatography-Ion Mobility Spectrometry to analyze the volatile profiles of the films is employed, to study the potential modification of the food in contact with the active film. These migrated compounds were shown to be closely related to both the mango extract additions and the film’s formulation themselves, showing different fingerprints depending on the film.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam

  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • González-Pinto, Lucía
  • Taltavull, Biel
  • Tarriño-León, María
  • Gallardo-García, María del Mar
  • Blanco Martín, Tania
  • Rodríguez-Pallares, Salud
  • Sánchez-Peña, Lucía
  • Moscoso, Miriam
  • Beceiro Casas, Alejandro
  • Oliver, Antonio
  • Bou, Germán
  • Arca-Suárez, Jorge
[Abstract] We report an outbreak of KPC-producing Pseudomonas aeruginosa in Spain, involving four patients and an environmental isolate recovered from a hospital sink. All isolates belonged to clone ST253 and exhibited difficult-to-treat resistance, including resistance to imipenem/relebactam and meropenem/vaborbactam. Genomic analysis confirmed a plasmid-encoded blaKPC-2 and OprD deficiency. Functional assays demonstrated synergy between KPC-2 production and porin loss on resistance to carbapenem/β-lactamase inhibitors. The findings highlight the clinical threat posed by KPC-producing P. aeruginosa., This study was supported by the Instituto de Salud Carlos III (ISCIII), through projects PI22/01212, PI23/00851, PI24/00010, and PI24/00920, and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055, and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, and Xunta de Galicia (IN607D 2021/012 to A.B., IN607A 2024/009 to G.B., and IN607D 2024/008 to J.A.-S.). G.P.-R. was financially supported by GAIN-Xunta de Galicia (IN606A 2025/020). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). M.M. was financially supported by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026). This work was also supported by the Fundación Pública Galega de Investigación Biomédica INIBIC, which provided financial support for the final publication of the article.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa

  • González-Pinto, Lucía
  • Monge-Olivares, Laura
  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • Sánchez-Peña, Lucía
  • Gomis-Font, María Antonia
  • Rodríguez-Pallares, Salud
  • Blanco Martín, Tania
  • López-Cerero, Lorena
  • Beceiro Casas, Alejandro
  • Bogaerts, Pierre
  • Oliver, Antonio
  • Bou, Germán
  • Arca-Suárez, Jorge
[Abstract] We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The blaOXA-1054 gene was cloned in parallel with blaOXA-48 and blaOXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The blaOXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa, including carbapenems and β-lactam/β-lactamase inhibitor combinations., This study was supported by Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI24/00010, PI24/00920, and PI25/00116 and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055 and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). M.A.G.-F. was financially supported by the ISCIII PFIS program (FI22/00039). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Juan Rodés program (JR25/00031). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales

  • Sánchez-Peña, Lucía
  • Rodríguez-Pallares, Salud
  • Blanco Martín, Tania
  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • González-Pinto, Lucía
  • López-Hernández, Inmaculada
  • Aracil, Belén
  • Beceiro Casas, Alejandro
  • Bou, Germán
  • Arca-Suárez, Jorge
Comparative study, [Abstract] We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied., This study was supported by the Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI23/00851, PI24/00920, and PI25/00116 co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CB21/13/00055). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Economía, Emprego e Industria, and Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas

  • López-Janeiro, Álvaro
  • Brizzi, Emilia
  • Ruz-Caracuel, Ignacio
  • Alexandru, Raluca
  • Andrea, Carlos de
  • Berjón, Alberto
  • Yébenes, Laura
  • Mendiola, Marta
  • Heredia-Soto, Victoria
  • Montero-Calle, Ana
  • Barderas, Rodrigo
  • Ríos, Vivian de los
  • Redondo, Andrés
  • Peláez-García, Alberto
  • Hardisson, David
[Data Availability Statement] The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD068004., Endometrial carcinoma is the most frequent gynecologic malignancy in western countries. In recent years, mutations in CTNNB1 have been associated with worse prognosis in low-risk carcinomas. However, there is a lack of understanding of the proteomic implications of CTNNB1 mutations in this type of tumor. In this study, we performed shotgun proteomics using Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples of CTNNB1 mutated and wild-type low-risk endometrial carcinomas. A publicly available proteomic and transcriptomic database was used to validate results. Differential protein expression and Gene Set Enrichment Analysis revealed dysregulation of pathways associated with cell keratinization, immune response modulation, and intracellular calcium regulation. CTNNB1 mutated tumors showed immune dysregulation at multiple levels including cytokine secretion, cell adhesion, and lymphocyte activation. These results were supported by tissue multiplex immunofluorescence analysis, demonstrating reduced CD8 tumor-infiltrating lymphocytes and different immune spatial interaction patterns. Intracellular calcium dysfunction was associated with key transcript dysregulation. We found an increased expression of CAMK2A and ROR2, suggesting a potential role for non-canonical Wnt pathway activation in CTNNB1 mutated tumors., This research was funded by Instituto de Salud Carlos III (ISCIII) (PI21/00920), co-financed by the European Regional Development Fund “A way to achieve Europe” (FEDER)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Intronic variants in the NFKB1 gene may influence hearing forecast in patients with unilateral sensorineural hearing loss in meniere's disease

  • Cabrera, S.
  • Sanchez, E.
  • Requena, T.
  • Martinez-Bueno, M.
  • Benitez, J.
  • Perez, N.
  • Trinidad, G.
  • Soto-Varela, A.
  • Santos-Perez, S.
  • Martin-Sanz, E.
  • Fraile, J.
  • Perez, P.
  • Alarcon-Riquelme, M.
  • Batuecas, A.
  • Espinosa-Sanchez, J.
  • Aran, I.
  • Lopez-Escamez, J.
Meniere's disease is an episodic vestibular syndrome associated with sensorineural hearing loss (SNHL) and tinnitus. Patients with MD have an elevated prevalence of several autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis and psoriasis), which suggests a shared autoimmune background. Functional variants of several genes involved in the NF-¿B pathway, such as REL, TNFAIP3, NFKB1 and TNIP1, have been associated with two or more immune-mediated diseases and allelic variations in the TLR10 gene may influence bilateral affectation and clinical course in MD. We have genotyped 716 cases of MD and 1628 controls by using the ImmunoChip, a high-density genotyping array containing 186 autoimmune loci, to explore the association of immune system related-loci with sporadic MD. Although no single nucleotide polymorphism (SNP) reached a genome-wide significant association (p<10-8), we selected allelic variants in the NF-kB pathway for further analyses to evaluate the impact of these SNPs in the clinical outcome of MD in our cohort. None of the selected SNPs increased susceptibility for MD in patients with uni or bilateral SNHL. However, two potential regulatory variants in the NFKB1 gene (rs3774937 and rs4648011) were associated with a faster hearing loss progression in patients with unilateral SNHL. So, individuals with unilateral MD carrying the C allele in rs3774937 or G allele in rs4648011 had a shorter mean time to reach hearing stage 3 (>40 dB HL) (log-rank test, corrected p values were p¿=¿0.009 for rs3774937 and p¿=¿0.003 for rs4648011, respectively). No variants influenced hearing in bilateral MD. Our data support that the allelic variants rs3774937 and rs4648011 can modify hearing outcome in patients with MD and unilateral SNHL.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain

  • Racz, Ildiko
  • Nadal i Roura, Xavier, 1980-
  • Alferink, Judith
  • Baños i Díez, Josep Eladi
  • Rehnelt, Jennifer
  • Rodríguez Codina, Martín Miguel
  • Pintado, Belén
  • Gutierrez-Adan, Alfonso
  • Sanguino, Elena
  • Bellora Pereyra, Nicolás
  • Manzanares, Jorge
  • Zimmer, Andreas
  • Maldonado, Rafael, 1961-
Nerve injuries often lead to neuropathic pain syndrome. The mechanisms contributing to this syndrome involve local inflammatory responses, activation of glia cells, and changes in the plasticity of neuronal nociceptive pathways. Cannabinoid CB(2) receptors contribute to the local containment of neuropathic pain by modulating glial activation in response to nerve injury. Thus, neuropathic pain spreads in mice lacking CB(2) receptors beyond the site of nerve injury. To further investigate the mechanisms leading to the enhanced manifestation of neuropathic pain, we have established expression profiles of spinal cord tissues from wild-type and CB(2)-deficient mice after nerve injury. An enhanced interferon-gamma (IFN-gamma) response was revealed in the absence of CB(2) signaling. Immunofluorescence stainings demonstrated an IFN-gamma production by astrocytes and neurons ispilateral to the nerve injury in wild-type animals. In contrast, CB(2)-deficient mice showed neuronal and astrocytic IFN-gamma immunoreactivity also in the contralateral region, thus matching the pattern of nociceptive hypersensitivity in these animals. Experiments in BV-2 microglia cells revealed that transcriptional changes induced by IFN-gamma in two key elements for neuropathic pain development, iNOS (inducible nitric oxide synthase) and CCR2, are modulated by CB(2) receptor signaling. The most direct support for a functional involvement of IFN-gamma as a mediator of CB(2) signaling was obtained with a double knock-out mouse strain deficient in CB(2) receptors and IFN-gamma. These animals no longer show the enhanced manifestations of neuropathic pain observed in CB(2) knock-outs. These data clearly demonstrate that the CB(2) receptor-mediated control of neuropathic pain is IFN-gamma dependent., This work was supported by grants from the National Institute on Drug Abuse (1R01-DA016768-0111) (R.M.,A.Z.), European Commission [Framework VI, GENADDICT OJ 2004/C164, 005166 (R.M., A.Z.); PHECOM, LSHM-CT-2007-037669 (R.M.)], Ministerio de Educación y Ciencia (BFU2004-00920/BFI; SAF2007-64062) (R.M.), Generalitat de Catalunya (R.M.), Deutsche Forschungsgemeinschaft (SFB645; FOR926) (A.Z.), and Bundesministerium für Bildung und Forschung (NGFN2) (A.Z.)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farre, Lourdes
  • McLean, Chelsea
  • Martínez Marti, Alexandre
  • Nadal, Ernest
  • Felip Font, Enriqueta
Càncer; Càncer de pulmó; Farmacoresistència, Cáncer; Cáncer de pulmón; Farmacorresistencia, Cancer; Lung cancer; Drug resistance, Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

  • Bosch-Barrera, J
  • Cedres Perez, Susana
  • Coves, J.
  • Garcia‑Campelo, Rosario
  • Guirado Risueño, María
  • Nadal, Ernest
Pautes clíniques, Mesotelioma pleural maligne; Tractament, Guías clínicas; Mesotelioma pleural maligno; Tratamiento, Clinical guidelines; Malignant pleural mesothelioma; Treatment, Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future., E. Nadal thanks the support of Health Institute Carlos III-FEDER (ISCIII) [PI14/01109 and PI18/00920].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain

  • Racz, Ildiko
  • Nadal i Roura, Xavier, 1980-
  • Alferink, Judith
  • Baños i Díez, Josep Eladi
  • Rehnelt, Jennifer
  • Martín Sánchez, Miquel, 1971-
  • Pintado, Belén
  • Gutierrez-Adan, Alfonso
  • Sanguino, Elena
  • Manzanares, Jorge
  • Zimmer, Andreas
  • Maldonado, Rafael, 1961-
Neuropathic pain is a clinical manifestation of nerve injury difficult to treat even with potent analgesic compounds. Here, we used different lines of genetically modified mice to clarify the role played by CB2 cannabinoid receptors in the regulation of the central immune responses leading to the development of neuropathic pain. CB2 knock-out mice and wild-type littermates were exposed to sciatic nerve injury, and both genotypes developed a similar hyperalgesia and allodynia in the ipsilateral paw. Most strikingly, knock-outs also developed a contralateral mirror image pain, associated with an enhanced microglial and astrocytic expression in the contralateral spinal horn. In agreement, hyperalgesia, allodynia, and microglial and astrocytic activation induced by sciatic nerve injury were attenuated in transgenic mice overexpressing CB2 receptors. These results demonstrate the crucial role of CB2 cannabinoid receptor in modulating glial activation in response to nerve injury. The enhanced manifestations of neuropathic pain were replicated in irradiated wild-type mice reconstituted with bone marrow cells from CB2 knock-outs, thus demonstrating the implication of the CB2 receptor expressed in hematopoietic cells in the development of neuropathic pain at the spinal cord., This work was supported by grants from the National Institute on Drug Abuse (1R01-DA016768-0111) (R.M.,A.Z.), European Commission [Framework VI, GENADDICT OJ 2004/C164, 005166 (R.M., A.Z.); PHECOM, LSHM-CT-2007-037669 (R.M.)], Ministerio de Educación y Ciencia (BFU2004-00920/BFI; SAF2007-64062) (R.M.), Generalitat de Catalunya (R.M.), Deutsche Forschungsgemeinschaft (SFB645; FOR926) (A.Z.), and Bundesministerium für Bildung und Forschung (NGFN2) (A.Z.).
Docta Complutense
Publicación Artículo científico (JournalArticle)

Treatment of Vitamin D Deficiency in Decompensated Patients with Cirrhosis Is Associated with Improvement in Frailty

  • Diaz-Ruiz, Raquel
  • Poca, Maria
  • Roman, Eva
  • Cuyas, Berta
  • Bañares, Irene
  • Morales, Angela
  • Hernandez Martinez-Esparza, Elvira
  • Panadero, Rocio
  • Velasco, Cristina
  • Rapado Castro, Marta
  • Bretón Lesmes, Irene
  • Bañares Cañizares, Rafael
  • Soriano, German
  • García Martínez, Rita
Abstract: Background/aim: Frailty is increasingly recognized as a relevant prognostic factor in patients with cirrhosis, regardless of liver failure. Vitamin D deficiency is frequent in these patients and has been related to frailty and sarcopenia, but the impact of its supplementation on frailty in cirrhosis is unknown. The aim was to evaluate the effect of vitamin D supplementation on frailty in patients with decompensated cirrhosis and vitamin D deficiency or insufficiency. Methods: We included patients with cirrhosis who had vitamin D deficiency or insufficiency following their hospitalization for acute decompensation. Vitamin D was supplemented according to current recommendations, as were other micronutrients if necessary. Patients were followed for one year to evaluate changes at 6 and 12 months in frailty (Fried frailty index), health-related quality of life (SF-36, CLDQ) and mood (HADS). Body composition was assessed by DXA at baseline and at 12 months. Results: We included 39 patients, 27 of whom reached the 6-month follow-up. Serum vitamin D increased at 6 and 12 months (p < 0.001 compared to baseline). Fried frailty index improved at the 6-month visit (p = 0.004), and handgrip strength improved at 6 (p = 0.001) and 12 (p = 0.002) months, similarly in women and men. At 12 months, we observed an increase in body mass index, right arm lean mass and total fat mass. Conclusions: A multifactorial nutritional intervention, especially vitamin D supplementation after discharge in decompensated, vitamin D-deficient patients with cirrhosis, was associated with an improvement in frailty, muscular strength and lean muscle mass. However, the increase in fat mass strengthens the recommendation for diet, exercise and weight supervision.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Marine crenarchaeotal membrane lipids in decapods, implications for the TEX 86 paleothermometer

  • Huguet, Carme|||0000-0001-8025-2010
  • Cartes Rodríguez, Joan E.
  • Damsté, Jaap S. Sinninghe
  • Schouten, Stefan
Pelagic Crenarchaeota produce glycerol dibiphytanyl glycerol tetraethers (GDGTs) as membrane lipids, and the GDGT composition changes according to growth temperature. This forms the basis of the TEX86 paleotemperature proxy. This ratio correlates with sea surface temperature (SST) despite the fact that Crenarchaeota are distributed through the water column. Therefore there must be mechanisms that transport the surface signal to sediments such as repackaging in fecal pellets, marine snow, mass falls after phytoplankton blooms, or daily migration. To study GDGT transport, we analyzed stomachs and intestines of Atlantic and Mediterranean decapods as they are one of the major megafaunal groups, are easy to sample, and occur in both pelagic and benthic environments. GDGTs were found in most decapods' guts. GDGT abundances are significantly lower in intestines, but TEX86-derived temperatures are not significantly different between stomachs and intestines (<1C), suggesting that TEX86 values are not altered during gut transit. Atlantic decapods show no difference in TEX86 values between benthic detritivors and pelagic predators. However, Mediterranean decapods show a substantial difference between macroplankton feeders and bentho-pelagic predators. This is probably related to the freshness of the material consumed. TEX86-derived temperatures in Atlantic decapods are close to the SST around the time of sampling, in agreement with stomach content analysis that shows fresh organic matter being ingested. For Mediterranean decapods, TEX86 temperatures are significantly higher than SST around the time of sampling. This can be partly attributed to the large variability between decapod specimens and the low amounts of fresh material found in their stomachs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • Homdedeu, Miquel de|||0000-0002-2865-1740
  • Sanchez-Moral, Lidia|||0000-0002-3795-8015
  • Violán, Concepció|||0000-0003-3309-5360
  • Ràfols, Neus
  • Ouchi, Dan|||0000-0002-8630-152X
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodriguez-Cortes, Alheli|||0000-0003-3617-0119
  • Arch Sisquella, Marta|||0000-0002-2120-1667
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi|||0000-0002-0968-7713
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Morros, Rosa|||0000-0001-6752-8748
  • Monfà, Ramon|||0000-0002-1324-3971
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Cardona, Pere-Joan|||0000-0001-5623-7873
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days. Biological sciences; Molecular biology; Immunology; Microbiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A longitudinal prospective study of active tuberculosis in a Western Europe setting, insights and findings

  • Romero-Tamarit, Arantxa
  • Vallès, Xavier|||0000-0002-4445-1490
  • Munar-García, María
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Saborit, Núria
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Roure, Silvia|||0000-0002-7982-0890
  • Antuori Torres, Adrián|||0000-0002-2782-3125
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Soriano-Arandes, Antoni|||0000-0001-9613-7228
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Espiau, María|||0000-0001-9697-7649
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Jiménez, Ma. Ángeles
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Molina Romero, Israel|||0000-0001-6642-7515
  • Casas, Xavier|||0000-0002-3892-9697
  • Domínguez-Álvarez, Marisol
  • Jové, Neus
  • Gogichadze, Nino|||0000-0001-7014-1608
  • Fonseca, Kaori L.|||0000-0002-7048-9740
  • Arias, Lilibeth|||0000-0002-2469-8832
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
This study investigates the potential of inflammatory parameters (IP), symptoms, and patient-related outcome measurements as biomarkers of severity and their ability to predict tuberculosis (TB) evolution. People with TB were included prospectively in the Stage-TB study conducted at five clinical sites in Barcelona (Spain) between April 2018 and December 2021. Data on demographics, epidemiology, clinical features, microbiology, and Sanit George Respiratory Questionnaire (SGRQ) and Kessler-10 as Health-Related Quality of Life (HRQoL) were collected at three time points during treatment. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte, and monocyte/lymphocyte ratios (NLR and MLR), complement factors C3, C4, and cH50, clinical and microbiological data, and HRQoL questionnaires were assessed at baseline, 2 months, and 6 months. Their ability to predict sputum culture conversion (SCC) and symptom presence after 2 months of treatment was also analysed. The study included 81 adults and 13 children with TB. The CRP, ESR, NLR, and MLR values, as well as the presence of symptoms, decreased significantly over time in both groups. Higher IP levels at baseline were associated with greater bacillary load and persistent symptoms. Clinical severity at baseline predicted a delayed SCC. Kessler-10 improved during follow-up, but self-reported lung impairment (SGRQ) persisted in all individuals after 6 months. IP levels may indicate disease severity, and sustained high levels are linked to lower treatment efficacy. Baseline clinical severity is the best predictor of SCC. Implementing health strategies to evaluate lung function and mental health throughout the disease process may be crucial for individuals with TB. The online version contains supplementary material available at 10.1007/s15010-024-02184-2.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

  • Bosch-Barrera, J
  • Cedres Perez, Susana
  • Coves, J.
  • Garcia‑Campelo, Rosario
  • Guirado Risueño, María
  • Nadal, Ernest
Pautes clíniques, Mesotelioma pleural maligne; Tractament, Guías clínicas; Mesotelioma pleural maligno; Tratamiento, Clinical guidelines; Malignant pleural mesothelioma; Treatment, Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future., E. Nadal thanks the support of Health Institute Carlos III-FEDER (ISCIII) [PI14/01109 and PI18/00920].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farre, Lourdes
  • McLean, Chelsea
  • Martínez Marti, Alexandre
  • Nadal, Ernest
  • Felip Font, Enriqueta
Càncer; Càncer de pulmó; Farmacoresistència, Cáncer; Cáncer de pulmón; Farmacorresistencia, Cancer; Lung cancer; Drug resistance, Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.